Compare Stocks

Date Range: 

 ShiseidoAstellas PharmaBeiGeneTakeda PharmaceuticalRoyalty Pharma
SymbolOTCMKTS:SSDOYOTCMKTS:ALPMYNASDAQ:BGNEOTCMKTS:TKPYYNASDAQ:RPRX
Price Information
Current Price$73.64$15.40$311.97$16.87$40.97
52 Week RangeHoldBuyHoldN/AHold
MarketRank™
Overall Score0.91.71.11.01.9
Analysis Score0.00.01.20.03.2
Community Score2.22.72.82.72.7
Dividend Score1.72.50.00.81.7
Ownership Score0.00.00.80.00.8
Earnings & Valuation Score0.63.10.61.31.3
Analyst Ratings
Consensus RecommendationHoldBuyHoldN/AHold
Consensus Price TargetN/AN/A$319.38N/A$51.88
% Upside from Price TargetN/AN/A2.37% upsideN/A26.62% upside
Trade Information
Market Cap$29.41 billion$28.67 billion$28.61 billion$26.36 billion$24.87 billion
Beta0.330.630.910.42N/A
Average Volume19,00075,989291,268979,6052,726,484
Sales & Book Value
Annual Revenue$10.38 billion$11.97 billion$428.21 million$15.99 billionN/A
Price / Sales2.832.4066.811.65N/A
Cashflow$3.53 per share$1.23 per shareN/A$2.24 per shareN/A
Price / Cash20.8512.47N/A7.52N/A
Book Value$11.93 per share$6.28 per share$15.87 per share$11.62 per shareN/A
Price / Book6.172.4519.661.45N/A
Profitability
Net Income$676.77 million$1.80 billion$-948,630,000.00$1.68 billionN/A
EPS$1.72$0.96($15.80)N/AN/A
Trailing P/E RatioN/A22.32N/A12.110.00
Forward P/E Ratio79.1810.13N/A15.23
P/E GrowthN/AN/AN/AN/A1.94
Net Margins-1.33%11.03%-569.22%7.84%N/A
Return on Equity (ROE)0.95%13.24%-56.81%11.35%N/A
Return on Assets (ROA)0.40%7.89%-39.93%5.57%N/A
Dividend
Annual Payout$0.27$0.29N/A$0.58$0.68
Dividend Yield0.37%1.88%N/A3.44%1.66%
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout Ratio15.70%30.21%N/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/A1 Years
Debt
Debt-to-Equity Ratio0.25%N/A0.04%0.48%0.59%
Current Ratio1.11%1.23%7.69%1.42%10.31%
Quick Ratio0.68%0.99%7.64%1.12%10.31%
Ownership Information
Institutional Ownership Percentage0.14%0.18%60.65%0.19%40.85%
Insider Ownership PercentageN/AN/A9.00%N/A2.50%
Miscellaneous
Employees40,00015,8835,300N/AN/A
Shares Outstanding399.39 million1.86 billion91.70 million1.56 billion607.11 million
Next Earnings Date5/11/2021 (Estimated)8/3/2021 (Estimated)8/5/2021 (Estimated)N/A5/11/2021 (Confirmed)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
Royalty Pharma plc (RPRX): Price Now Near $41.94; Daily Chart Shows Downtrend on 100 Day BasisRoyalty Pharma plc (RPRX): Price Now Near $41.94; Daily Chart Shows Downtrend on 100 Day Basis
etfdailynews.com - May 8 at 1:47 AM
Royalty Pharma to Present at Upcoming Investor ConferencesRoyalty Pharma to Present at Upcoming Investor Conferences
benzinga.com - May 7 at 9:14 AM
Is Royalty Pharma plcs (NASDAQ:RPRX) 17% ROE Strong Compared To Its Industry?Is Royalty Pharma plc's (NASDAQ:RPRX) 17% ROE Strong Compared To Its Industry?
nasdaq.com - May 6 at 2:38 PM
Royalty Pharma: A Potentially Long-Term Dividend InvestmentRoyalty Pharma: A Potentially Long-Term Dividend Investment
seekingalpha.com - May 5 at 10:59 AM
Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021
finance.yahoo.com - April 21 at 7:00 PM
MSCI Announces Strategic Alliance With Royalty Pharma to Launch Life Sciences IndexesMSCI Announces Strategic Alliance With Royalty Pharma to Launch Life Sciences Indexes
uk.finance.yahoo.com - April 21 at 1:59 PM
Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences IndexesRoyalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes
finance.yahoo.com - April 21 at 8:59 AM
Royalty Pharma Plc (RPRX)Royalty Pharma Plc (RPRX)
investing.com - April 18 at 10:37 PM
Royalty Pharma Plc (RPRX) EVP, Investments & GC George W. Lloyd Sold $2.9 million of SharesRoyalty Pharma Plc (RPRX) EVP, Investments & GC George W. Lloyd Sold $2.9 million of Shares
uk.finance.yahoo.com - April 16 at 11:05 PM
Royalty Pharma Declares Second-Quarter 2021 DividendRoyalty Pharma Declares Second-Quarter 2021 Dividend
finance.yahoo.com - April 15 at 9:42 AM
Insider Sells Royalty Pharmas SharesInsider Sells Royalty Pharma's Shares
benzinga.com - April 14 at 2:33 PM
Royalty Pharma plc (NASDAQ:RPRX) EVP George W. Lloyd Sells 449 SharesRoyalty Pharma plc (NASDAQ:RPRX) EVP George W. Lloyd Sells 449 Shares
americanbankingnews.com - April 14 at 10:46 AM
Royalty Pharma Shows PromiseRoyalty Pharma Shows Promise
realmoney.thestreet.com - April 9 at 1:34 PM
Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSKRoyalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
finance.yahoo.com - April 1 at 10:23 AM
Royalty Pharma Appoints Henry A. Fernandez as Lead Independent DirectorRoyalty Pharma Appoints Henry A. Fernandez as Lead Independent Director
finance.yahoo.com - March 30 at 8:13 AM
Is Royalty Pharma a Biotech Stock Worth Buying?Is Royalty Pharma a Biotech Stock Worth Buying?
stocknews.com - March 26 at 12:39 PM
SYF vs. RPRX: Which Stock Should Value Investors Buy Now?SYF vs. RPRX: Which Stock Should Value Investors Buy Now?
msn.com - March 25 at 3:51 PM
Royalty Pharma Plc (RPRX) EVP, Investments & GC George W. Lloyd Sold $2.5 million of SharesRoyalty Pharma Plc (RPRX) EVP, Investments & GC George W. Lloyd Sold $2.5 million of Shares
finance.yahoo.com - March 24 at 7:51 PM
Royalty Pharma Plc (RPRX) EVP & CFO Terrance P. Coyne Sold $4.5 million of SharesRoyalty Pharma Plc (RPRX) EVP & CFO Terrance P. Coyne Sold $4.5 million of Shares
finance.yahoo.com - March 6 at 1:13 AM
Relative Strength Alert For Royalty PharmaRelative Strength Alert For Royalty Pharma
nasdaq.com - March 4 at 7:52 PM
Royalty Pharma: 4Q Earnings SnapshotRoyalty Pharma: 4Q Earnings Snapshot
sfgate.com - February 17 at 12:49 PM
Repros Therapeutics (RPRX) Q4 2020 Earnings Call TranscriptRepros Therapeutics (RPRX) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 17 at 12:48 PM
Royalty Pharma Raises Dividend by 13%Royalty Pharma Raises Dividend by 13%
dividend.com - February 17 at 7:48 AM
Royalty Pharma plc - Ordinary Shares - Class A to Host Earnings CallRoyalty Pharma plc - Ordinary Shares - Class A to Host Earnings Call
finance.yahoo.com - February 17 at 7:48 AM
Royalty Pharma Reports Q4 2020 and Full-Year ResultsRoyalty Pharma Reports Q4 2020 and Full-Year Results
finance.yahoo.com - February 17 at 7:48 AM
DateCompanyBrokerageAction
11/11/2020ShiseidoDaiwa Capital MarketsUpgrade
9/30/2020ShiseidoJefferies Financial GroupUpgrade
9/4/2020ShiseidoThe Goldman Sachs GroupDowngrade
8/7/2020ShiseidoCLSADowngrade
7/28/2020ShiseidoMorgan StanleyDowngrade
6/24/2020ShiseidoJPMorgan Chase & Co.Upgrade
9/13/2018Astellas PharmaDeutsche Bank AktiengesellschaftDowngrade
3/16/2021BeiGeneHSBCBoost Price Target
3/8/2021BeiGeneChina Renaissance SecuritiesInitiated Coverage
2/25/2021BeiGeneCowenBoost Price Target
1/12/2021BeiGenePiper SandlerBoost Price Target
12/8/2020BeiGeneLADENBURG THALM/SH SHUpgrade
11/19/2020BeiGeneSVB LeerinkBoost Price Target
11/6/2020BeiGeneMaxim GroupDowngrade
3/13/2020BeiGeneMacquarieUpgrade
11/9/2020Royalty PharmaUBS GroupUpgrade
7/14/2020Royalty PharmaEvercore ISIInitiated Coverage
7/13/2020Royalty PharmaBank of AmericaInitiated Coverage
7/13/2020Royalty PharmaCitigroupInitiated Coverage
7/13/2020Royalty PharmaSunTrust BanksInitiated Coverage
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.